Global Schizophrenia Treatments Market Size, Status and Forecast 2019-2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Schizophrenia Treatments Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Atypical Antipsychotics
- 1.4.3 Phenothiazine Antipsychotics
- 1.4.4 Thioxanthenes
- 1.4.5 Miscellaneous Antipsychotic Agents
- 1.5 Market by Application
- 1.5.1 Global Schizophrenia Treatments Market Share by Application (2014-2025)
- 1.5.2 Hospital Pharmacies
- 1.5.3 Drug Stores
- 1.5.4 Retail Pharmacies
- 1.5.5 E-Commerce
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Schizophrenia Treatments Market Size
- 2.2 Schizophrenia Treatments Growth Trends by Regions
- 2.2.1 Schizophrenia Treatments Market Size by Regions (2014-2025)
- 2.2.2 Schizophrenia Treatments Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Schizophrenia Treatments Market Size by Manufacturers
- 3.1.1 Global Schizophrenia Treatments Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Schizophrenia Treatments Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Schizophrenia Treatments Market Concentration Ratio (CR5 and HHI)
- 3.2 Schizophrenia Treatments Key Players Head office and Area Served
- 3.3 Key Players Schizophrenia Treatments Product/Solution/Service
- 3.4 Date of Enter into Schizophrenia Treatments Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Schizophrenia Treatments Market Size by Type (2014-2019)
- 4.2 Global Schizophrenia Treatments Market Size by Application (2014-2019)
5 United States
- 5.1 United States Schizophrenia Treatments Market Size (2014-2019)
- 5.2 Schizophrenia Treatments Key Players in United States
- 5.3 United States Schizophrenia Treatments Market Size by Type
- 5.4 United States Schizophrenia Treatments Market Size by Application
6 Europe
- 6.1 Europe Schizophrenia Treatments Market Size (2014-2019)
- 6.2 Schizophrenia Treatments Key Players in Europe
- 6.3 Europe Schizophrenia Treatments Market Size by Type
- 6.4 Europe Schizophrenia Treatments Market Size by Application
7 China
- 7.1 China Schizophrenia Treatments Market Size (2014-2019)
- 7.2 Schizophrenia Treatments Key Players in China
- 7.3 China Schizophrenia Treatments Market Size by Type
- 7.4 China Schizophrenia Treatments Market Size by Application
8 Japan
- 8.1 Japan Schizophrenia Treatments Market Size (2014-2019)
- 8.2 Schizophrenia Treatments Key Players in Japan
- 8.3 Japan Schizophrenia Treatments Market Size by Type
- 8.4 Japan Schizophrenia Treatments Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Schizophrenia Treatments Market Size (2014-2019)
- 9.2 Schizophrenia Treatments Key Players in Southeast Asia
- 9.3 Southeast Asia Schizophrenia Treatments Market Size by Type
- 9.4 Southeast Asia Schizophrenia Treatments Market Size by Application
10 India
- 10.1 India Schizophrenia Treatments Market Size (2014-2019)
- 10.2 Schizophrenia Treatments Key Players in India
- 10.3 India Schizophrenia Treatments Market Size by Type
- 10.4 India Schizophrenia Treatments Market Size by Application
11 Central & South America
- 11.1 Central & South America Schizophrenia Treatments Market Size (2014-2019)
- 11.2 Schizophrenia Treatments Key Players in Central & South America
- 11.3 Central & South America Schizophrenia Treatments Market Size by Type
- 11.4 Central & South America Schizophrenia Treatments Market Size by Application
12 International Players Profiles
- 12.1 Johnson and Johnson
- 12.1.1 Johnson and Johnson Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Schizophrenia Treatments Introduction
- 12.1.4 Johnson and Johnson Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.1.5 Johnson and Johnson Recent Development
- 12.2 Bristol-Myers Squibb
- 12.2.1 Bristol-Myers Squibb Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Schizophrenia Treatments Introduction
- 12.2.4 Bristol-Myers Squibb Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.2.5 Bristol-Myers Squibb Recent Development
- 12.3 Otsuka
- 12.3.1 Otsuka Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Schizophrenia Treatments Introduction
- 12.3.4 Otsuka Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.3.5 Otsuka Recent Development
- 12.4 AstraZeneca
- 12.4.1 AstraZeneca Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Schizophrenia Treatments Introduction
- 12.4.4 AstraZeneca Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.4.5 AstraZeneca Recent Development
- 12.5 Sumitomo Dainippon Pharma
- 12.5.1 Sumitomo Dainippon Pharma Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Schizophrenia Treatments Introduction
- 12.5.4 Sumitomo Dainippon Pharma Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.5.5 Sumitomo Dainippon Pharma Recent Development
- 12.6 Eli Lilly
- 12.6.1 Eli Lilly Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Schizophrenia Treatments Introduction
- 12.6.4 Eli Lilly Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.6.5 Eli Lilly Recent Development
- 12.7 Alkermes
- 12.7.1 Alkermes Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Schizophrenia Treatments Introduction
- 12.7.4 Alkermes Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.7.5 Alkermes Recent Development
- 12.8 Vanda Pharmaceuticals
- 12.8.1 Vanda Pharmaceuticals Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Schizophrenia Treatments Introduction
- 12.8.4 Vanda Pharmaceuticals Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.8.5 Vanda Pharmaceuticals Recent Development
- 12.9 ALLERGAN
- 12.9.1 ALLERGAN Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Schizophrenia Treatments Introduction
- 12.9.4 ALLERGAN Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.9.5 ALLERGAN Recent Development
- 12.10 Pfizer
- 12.10.1 Pfizer Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Schizophrenia Treatments Introduction
- 12.10.4 Pfizer Revenue in Schizophrenia Treatments Business (2014-2019)
- 12.10.5 Pfizer Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Schizophrenia is a mental disorder characterized by abnormal behavior and failure to understand reality.
The schizophrenia treatment market is expected to witness a high growth over the forecast period owing to the increasing incidence of schizophrenia.
In 2018, the global Schizophrenia Treatments market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Schizophrenia Treatments status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Schizophrenia Treatments development in United States, Europe and China.
The key players covered in this study
Johnson and Johnson
Bristol-Myers Squibb
Otsuka
AstraZeneca
Sumitomo Dainippon Pharma
Eli Lilly
Alkermes
Vanda Pharmaceuticals
ALLERGAN
Pfizer
Market segment by Type, the product can be split into
Atypical Antipsychotics
Phenothiazine Antipsychotics
Thioxanthenes
Miscellaneous Antipsychotic Agents
Market segment by Application, split into
Hospital Pharmacies
Drug Stores
Retail Pharmacies
E-Commerce
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Schizophrenia Treatments status, future forecast, growth opportunity, key market and key players.
To present the Schizophrenia Treatments development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Schizophrenia Treatments are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.